Mn Services Vermogensbeheer B.V. Acquires 4,966 Shares of Zoetis Inc. $ZTS

Mn Services Vermogensbeheer B.V. lifted its stake in Zoetis Inc. (NYSE:ZTS) by 2.9% during the fourth quarter, Holdings Channel reports. The fund owned 173,669 shares of the company’s stock after acquiring an additional 4,966 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Zoetis were worth $21,851,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Summit Place Financial Advisors LLC boosted its position in Zoetis by 0.4% during the third quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company’s stock worth $2,834,000 after purchasing an additional 76 shares during the period. First County Bank CT raised its position in shares of Zoetis by 5.4% in the third quarter. First County Bank CT now owns 1,535 shares of the company’s stock valued at $225,000 after purchasing an additional 79 shares during the period. CWA Asset Management Group LLC lifted its stake in shares of Zoetis by 1.1% in the third quarter. CWA Asset Management Group LLC now owns 7,236 shares of the company’s stock worth $1,059,000 after buying an additional 80 shares during the last quarter. Balefire LLC lifted its stake in shares of Zoetis by 3.5% in the third quarter. Balefire LLC now owns 2,463 shares of the company’s stock worth $360,000 after buying an additional 84 shares during the last quarter. Finally, Evergreen Capital Management LLC boosted its holdings in shares of Zoetis by 3.3% during the 3rd quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company’s stock worth $394,000 after buying an additional 85 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $118.02 on Wednesday. Zoetis Inc. has a 1-year low of $113.29 and a 1-year high of $172.23. The firm has a market capitalization of $49.82 billion, a PE ratio of 19.60, a PEG ratio of 1.78 and a beta of 0.95. The business’s 50 day moving average is $123.12 and its 200-day moving average is $128.57. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Analysts Set New Price Targets

A number of research firms have weighed in on ZTS. Barclays started coverage on shares of Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price for the company. Bank of America lifted their price objective on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. Weiss Ratings cut Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a research note on Monday, December 15th. Finally, William Blair reaffirmed an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.